Weekly ReportAug 31 – Sep 6, 2026
Anesthesiology, week 36 edition
We read 229 papers and selected 3.
Summary
This week’s anesthesiology literature emphasized precision, safety, and scalable perioperative evidence generation. Mechanistic work showed that emergence from anesthesia depends on the specific anesthetic agent, while clinical studies supported targeted analgesia, improved postoperative nausea and vomiting prevention, and adaptive platform-trial infrastructure. Important negative findings also emerged: spinal anesthesia was not clearly superior to general anesthesia for hip-fracture surgery, and several established or emerging interventions require more selective use because benefits remain uncertain or harms may be substantial.
Selected Articles
1. The role of ventral tegmental area dopamine neurons in emergence from dexmedetomidine, fentanyl, and ketamine anesthesia in rats.
In a rat optogenetic study, stimulation of ventral tegmental area dopamine neurons strongly promoted emergence from dexmedetomidine-induced unconsciousness, had no benefit during fentanyl anesthesia, and modestly delayed emergence from ketamine. The findings demonstrate that dopamine-mediated arousal is agent-specific rather than a universal reversal pathway.
Impact: This study challenges the assumption that one arousal circuit can reverse unconsciousness caused by mechanistically diverse anesthetics. It provides a biologically coherent framework for developing agent-specific emergence interventions.
Clinical Implications: The findings do not yet justify clinical manipulation of ventral tegmental area dopamine neurons, but they support tailoring future pharmacologic or neuromodulatory emergence strategies to the anesthetic agent. They also caution against extrapolating a successful dexmedetomidine reversal strategy to opioids or ketamine.
Key Findings
- Optogenetic stimulation restored righting during dexmedetomidine-induced unconsciousness with a hazard ratio of 27.7.
- The intervention did not improve fentanyl emergence and modestly delayed ketamine emergence.
- Dexmedetomidine responders showed reduced low-frequency EEG power below 12 Hz.
2. A perioperative medicine platform trial (PROMPT) evaluating interventions to reduce the risk of infection and other major complications after surgery: rationale and design.
PROMPT is a multicentre Bayesian adaptive platform trial designed to evaluate multiple perioperative interventions for surgical-site infection and other major postoperative complications. Its master protocol allows interventions to be added, replaced, or stopped as evidence accumulates and includes patient-centered outcomes such as quality of recovery and days alive and at home.
Impact: PROMPT provides reusable infrastructure for testing successive perioperative interventions within one efficient trial framework. Its ability to identify benefit, harm, futility, equivalence, or inferiority could accelerate translation of reliable evidence into anesthesiology and surgical practice.
Clinical Implications: The platform may improve evaluation of oxygen strategies, infection-prevention measures, and other perioperative interventions across diverse surgical populations. However, this publication reports the protocol and design rather than clinical outcomes, so practice-changing conclusions are not yet available.
Key Findings
- PROMPT is a multicentre Bayesian adaptive platform trial using a master protocol and domain-specific appendices.
- The design can assess superiority, efficacy, equivalence, inferiority, harm, and futility as evidence accumulates.
- Primary and secondary outcomes include surgical-site infection, major complications, quality of recovery, and days alive and at home.
3. A multicenter parallel-group double-blind randomized placebo-controlled phase III clinical trial of generic aprepitant QLG2174 for the prevention of postoperative nausea and vomiting.
In a multicentre, double-blind, placebo-controlled phase III trial of 515 high-risk Chinese patients undergoing elective laparoscopic surgery, intravenous generic aprepitant increased the 24-hour complete-response rate from 44.0% to 70.7%. The adjusted absolute improvement was 26.6 percentage points, supporting clinically meaningful prevention of postoperative nausea and vomiting.
Impact: This large phase III randomized trial addresses a common, patient-important anesthetic complication and showed a substantial absolute improvement in complete response. It offers potentially practice-relevant evidence for incorporating generic aprepitant into multimodal prophylaxis for selected high-risk patients.
Clinical Implications: Intravenous generic aprepitant shortly before induction may be considered for patients with at least two postoperative nausea and vomiting risk factors undergoing elective laparoscopic abdominal or gynecologic surgery. Adoption should account for local formulary, cost, safety, and combination-prophylaxis strategies.
Key Findings
- The trial enrolled 515 patients undergoing elective laparoscopic gynecologic or abdominal surgery with at least two risk factors.
- The 24-hour complete-response rate was 70.7% with QLG2174 versus 44.0% with placebo.
- The adjusted absolute treatment difference was 26.6 percentage points, with a 95% confidence interval of 18.4 to 34.7 percentage points.